Boston Family Office LLC Lowers Stake in Celgene Corporation (CELG)

Boston Family Office LLC lowered its position in Celgene Corporation (NASDAQ:CELG) by 5.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 136,279 shares of the biopharmaceutical company’s stock after selling 7,561 shares during the period. Celgene Corporation makes up approximately 2.1% of Boston Family Office LLC’s holdings, making the stock its 4th largest position. Boston Family Office LLC’s holdings in Celgene Corporation were worth $16,957,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of CELG. Diversified Trust Co raised its position in shares of Celgene Corporation by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 9 shares in the last quarter. Quadrant Capital Group LLC raised its position in shares of Celgene Corporation by 0.8% in the first quarter. Quadrant Capital Group LLC now owns 4,073 shares of the biopharmaceutical company’s stock worth $492,000 after buying an additional 34 shares in the last quarter. Cadence Bank NA raised its position in shares of Celgene Corporation by 0.6% in the first quarter. Cadence Bank NA now owns 7,496 shares of the biopharmaceutical company’s stock worth $933,000 after buying an additional 45 shares in the last quarter. Washington Trust Bank raised its position in shares of Celgene Corporation by 1.3% in the first quarter. Washington Trust Bank now owns 3,613 shares of the biopharmaceutical company’s stock worth $450,000 after buying an additional 46 shares in the last quarter. Finally, Private Capital Advisors Inc. raised its position in shares of Celgene Corporation by 0.3% in the first quarter. Private Capital Advisors Inc. now owns 15,050 shares of the biopharmaceutical company’s stock worth $1,873,000 after buying an additional 50 shares in the last quarter. 78.34% of the stock is currently owned by institutional investors.

Shares of Celgene Corporation (NASDAQ:CELG) traded down 0.08% during trading on Wednesday, reaching $131.26. 2,218,457 shares of the company’s stock were exchanged. The company has a market capitalization of $102.69 billion, a PE ratio of 40.65 and a beta of 1.89. The company has a 50 day moving average price of $134.03 and a 200-day moving average price of $124.75. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $139.00.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.44 earnings per share. On average, equities analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Boston Family Office LLC Lowers Stake in Celgene Corporation (CELG)” was posted by BBNS and is the property of of BBNS. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/boston-family-office-llc-has-16-96-million-position-in-celgene-corporation-celg-updated-updated-updated/1252075.html.

A number of analysts have recently commented on the company. Jefferies Group LLC set a $154.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a report on Saturday, May 13th. BTIG Research downgraded Celgene Corporation from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $96.93 to $131.70 in a report on Friday, June 30th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective for the company in a report on Thursday, August 10th. Robert W. Baird restated an “outperform” rating and set a $162.00 price objective on shares of Celgene Corporation in a report on Monday, May 22nd. Finally, SunTrust Banks, Inc. set a $150.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $147.00.

In related news, Director Ernest Mario sold 18,506 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the sale, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the sale, the insider now directly owns 4,004 shares in the company, valued at approximately $481,200.72. The disclosure for this sale can be found here. In the last three months, insiders sold 253,761 shares of company stock worth $33,792,445. 0.95% of the stock is currently owned by insiders.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns


Leave a Reply

 
© 2006-2017 BBNS.